ECOR Share Price Performance
US$4.71
-6.64 (-58.50%)
77.8% undervalued intrinsic discount
US$21.24
Fair Value
Price US$4.71
AnalystConsensusTarget US$21.24
AnalystLowTarget US$12.00
AnalystHighTarget US$25.20
Fair ValueUS$21.40
Share Pricen/a
electroCore, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 25 Fair Values set on narratives written by author
ECOR Community Narratives
AN
Fair Value US$21.4 78.0% undervalued intrinsic discount
Chronic Disorder Trends Will Expand Noninvasive Neuromodulation Adoption
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
Fair Value US$12 60.8% undervalued intrinsic discount
Slow VA Adoption Will Hinder Operations Yet Will Reveal Opportunity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$25.2 81.3% undervalued intrinsic discount
Aging Population Will Expand gammaCore Adoption For Neuromodulation
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Aging Population Will Expand gammaCore Adoption For Neuromodulation
Key Takeaways Rapid integration of acquisitions and talent enables electroCore to dominate large pain and neuromodulation markets, supporting accelerated revenue and margin growth. Expansion into new FDA indications, digital health, and aging demographics positions electroCore for recurring high-margin revenues and sustained long-term growth.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$25.2
81.3% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
39.63% p.a.
Profit Margin
27.46%
Future PE
13.66x
Share price in 2028
US$24.08
Slow VA Adoption Will Hinder Operations Yet Will Reveal Opportunity
Key Takeaways Slow market penetration, regulatory hurdles, and persistent operating losses pose risks to revenue growth, funding stability, and future profitability. Rising digital health competition and potential patent issues threaten product differentiation, price strength, and long-term market position.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$12
60.8% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
27.6% p.a.
Profit Margin
12.49%
Future PE
18.77x
Share price in 2028
US$11.49
Chronic Disorder Trends Will Expand Noninvasive Neuromodulation Adoption
Key Takeaways Expansion into new indications and integration of acquired products is expected to drive broad, long-term demand growth and greater operating leverage. Emphasis on digital health, recurring revenue models, and strategic investments positions the company for scalable margin improvement and accelerated earnings.Read more
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
US$21.4
78.0% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
32.58% p.a.
Profit Margin
20.23%
Future PE
18.42x
Share price in 2028
US$20.49
Recently Updated Narratives
AN
Slow VA Adoption Will Hinder Operations Yet Will Reveal Opportunity
Fair Value: US$12 60.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Population Will Expand gammaCore Adoption For Neuromodulation
Fair Value: US$25.2 81.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Chronic Disorder Trends Will Expand Noninvasive Neuromodulation Adoption
Fair Value: US$21.4 78.0% undervalued intrinsic discount
11 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
electroCore, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.77
- 86.04%
- -47.46%
- -608.2%
About ECOR
- Founded
- 2005
- Employees
- 73
- CEO
- WebsiteView website
electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation (“nVNS”) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an, app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
